Memantine for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if memantine, a drug used for Alzheimer's disease, can help men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. It may be especially relevant if you also have Alzheimer's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Have a type of advanced prostate cancer called metastatic castration-resistant prostate cancer (mCRPC) that has not gotten better after 1 or 2 previous treatments
- Be willing to have your health followed for a long time
- Be well enough to do everyday activities with little or no help (ECOG score 0-1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This trial tests a new type of immune cell therapy (called AB-3028) designed to recognize and attack prostate cancer cells that have the PSMA protein on their surface. It's for people whose prostate cancer has spread and is no longer controlled by hormone therapy.
This trial tests a new drug combination that uses a radioactive molecule to find and treat prostate cancer cells that have spread and are no longer responding to hormone therapy. It may be an option for men with a specific protein called PSMA on their cancer cells.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This trial tests whether cannabidiol (CBD), a non-intoxicating cannabis compound, can help relieve pain in patients with advanced prostate cancer that has stopped responding to standard treatments. You would take CBD daily alongside your current morphine pain medication.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.